The biotechnology company, Cassava Sciences Inc. (SAVA), a developer of drugs for nervous system disorders, has been seeing its stock price rising 43.83% in early trades floating at $126.50 (07:12 a.m. EST). The rise could be attributed to results announced by the company on Tuesday of an interim analysis from an open-label study of the company’s leading drug candidate simufilam for the treatment of Alzheimer’s disease.
The focus of Cassava Sciences is to identify and establish innovations for chronic diseases that are neurodegenerative. Cassava Sciences has merged state-of-the-art technologies with new neurobiology discoveries over the last 10 years to establish innovative solutions for Alzheimer’s disease. A chronic brain condition that destroys memory and reasoning skills is Alzheimer’s disease.
The firm announced this week the findings of an interim review of simufilam, it’s a lead drug candidate for the treatment of Alzheimer’s disease, from an open-label trial. The cognitive abilities and activity ratings of patients have increased after six months of simufilam medication, without any health complications.
Six months of simufilam therapy increased cognitive scores by 1.6 points on ADAS-Cog11, a 10 percent mean increase from baseline to month 6, in a clinical trial sponsored by the National Institutes of Health and performed by Cassava Sciences. Simufilam also increased dementia-related behavior, such as depression, paranoia, and agitation, in these same patients by 1.3 points on the Neuropsychiatric Inventory, a mean increase of 29 percent from baseline to month 6.
There are no medication treatments at present to stop Alzheimer’s disease, even less to change its course. Approximately 5.8 million people are currently diagnosed with Alzheimer’s disease in the United States alone, and approximately 487,000 people aged 65 or older encountered Alzheimer’s disease in 2019. In the years ahead, the number of people living with Alzheimer’s disease is projected to rise significantly, resulting in a rising financial and social strain.